Development of a pathway for formulary approval for medicines for the treatment of young people with Attention Deficit Hyperactivity Disorder (ADHD) in a secondary care setting in UK jointly by chief Pharmacist and Paediatrician (specialist)


For full access to this content, log in to an existing user account or you can create a new account.